AstraZeneca

Showing 15 posts of 785 posts found.

Crestor victory lifts AstraZeneca

July 1, 2010
Sales and Marketing AstraZeneca, Crestor

AstraZeneca has defeated a challenge to the US patent on its blockbuster cholesterol drug Crestor. A US District Judge in …

AstraZeneca and Targacept begin depression trials

June 24, 2010
Research and Development AstraZeneca, Targacept, depression

AstraZeneca and Targacept have begun enrolling patients in phase III trials for TC-5214, a new treatment for depression. The new …

MedImmune Ventures appoints Ron Laufer

June 18, 2010
Research and Development AstraZeneca, MedImmune, appointment, research and development

Ron Laufer has joined MedImmune’s venture capital arm as senior managing director. The company, which is the worldwide biologics unit …

Zactima promising in rare thyroid cancer

June 11, 2010
Research and Development, Sales and Marketing AstraZeneca, thyroid cancer, zactima

AstraZeneca’s Zactima (vandetanib) will be filed with regulators later this year as a treatment for thyroid cancer after promising results. …

Nexium

AZ submits Nexium-aspirin combination for EU approval

June 7, 2010
Sales and Marketing AstraZeneca, Nexium, aspirin

AstraZeneca is seeking European approval for a new version of its anti-ulcer blockbuster Nexium that combines the pill with aspirin. …

Pfizer R&D head exits for AstraZeneca

May 27, 2010
Research and Development AstraZeneca, Pfizer, appointment, research and development

One of Pfizer’s two heads of research and development Martin Mackay is to leave the company for rivals AstraZeneca. Only …

AZ signs tuberculosis drug discovery deal

May 6, 2010
Research and Development AstraZeneca, India, TB, tuberculosis

AstraZeneca and the Global Alliance for TB Drug Development are to collaborate on the discovery and development of drugs to treat tuberculosis.The two …

Crestor

Crestor gains prevention licence in Europe

April 27, 2010
Sales and Marketing AstraZeneca, Crestor, statin

AstraZeneca’s statin treatment Crestor has been approved in the European Union for the prevention of major cardiovascular events in patients …

European approval for ‘double strength’ Faslodex

March 19, 2010
Sales and Marketing AstraZeneca, Faslodex, breast cancer

AstraZeneca’s Faslodex has expanded its European licence after winning approval to treat women with hormone receptor-positive breast cancer in a …

UK hit hard as AstraZeneca reveals R&D cuts

March 3, 2010
Research and Development AstraZeneca, job cuts

Nearly 3,500 R&D jobs will be affected at AstraZeneca in the coming months as the pharmaceutical giant exits discovery research …

Brennan rejects generics diversification model

February 11, 2010
Sales and Marketing AstraZeneca, biosimilars, em, generics, industry

AstraZeneca’s chief executive David Brennan has rejected the strategy of diversification into generics and biosimilars being pursued by many of …

Job cuts at GlaxoSmithKline and AstraZeneca

February 2, 2010
Research and Development, Sales and Marketing AstraZeneca, GlaxoSmithKline

Britain’s two biggest pharma companies GlaxoSmithKline and AstraZeneca are poised to make deep job cuts as business models continue to …

BBC highlights AZ’s Seroquel woes

January 27, 2010
Sales and Marketing AstraZeneca, Seroquel, industry reputation

AstraZeneca’s ongoing US legal battle over its antipsychotic drug Seroquel was highlighted this week in a BBC radio programme. AstraZeneca …

AstraZeneca continues personalised healthcare push

January 19, 2010
Sales and Marketing AstraZeneca, Dako, Diagnostics, Iressa

AstraZeneca and cancer diagnostics specialist Dako Denmark are to develop companion diagnostics for a number of the pharma company’s oncology …

AstraZeneca taps Korean firm for antibiotics

January 15, 2010
Research and Development Asia, AstraZeneca, CrystalGenomics, Korea, anti-infectives

AstraZeneca has signed another licensing deal to bolster its anti-infectives business, this time signing a deal with Korean company CrystalGenomics …

The Gateway to Local Adoption Series

Latest content